Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
复制标题
TUNEL技术检测临床局限性前列腺癌联合内分泌治疗前后细胞凋亡情况
DOI：
10.1136/jcp.50.5.384
复制
发表时间：
1997
影响因子：
3.4
通讯作者：
Guardamagna D Colloi
中科院分区：
文献类型：
--
作者：
M. Colecchia;B. Frigo;Del Boca;A. Guardamagna;A. Zucchi;D. Colloi;Leopardi;C. Del;Guardamagna D Colloi
目的：观察前列腺癌联合内分泌治疗3个月后的细胞凋亡情况，探讨其与肿瘤分级、肿瘤分期以及治疗前后肿瘤细胞中p53和bcl-2免疫组化检测的关系。方法：联合内分泌治疗3个月后切除的26例福尔马林固定、石蜡包埋核心活检及相应的前列腺切除术标本，采用末端脱氧核苷酸转移酶介导的dutp -生物素nick end标记（TUNEL）法分析凋亡细胞的存在，免疫组织化学分析p53和bcl-2的过表达。结果：26例腺癌在诊断时均被临床定位。在联合内分泌治疗前的活检中，凋亡指数在0.09% ~ 1.73%之间变化，肿瘤分级在Gleason评分1 ~ 8之间。治疗前细胞凋亡计数平均值（SD）为0.71%（0.50）。活检中凋亡计数升高与Gleason评分升高之间存在显著相关性（p = 0.005）。治疗3个月后，肿瘤细胞凋亡百分比的增加与肿瘤分期无关，而与Gleason分级显著相关（p = 0.0018），所有肿瘤的Gleason评分均< 7。8例细胞凋亡指数高于治疗前2倍以上。其余肿瘤显示较少的凋亡指数增加（5例）或凋亡细胞百分比减少。综合内分泌治疗后，细胞凋亡指数总体适度升高，差异无统计学意义（p = 0.8）。治疗前后，所有病例均无p53的免疫反应性，而在13例肿瘤中，有5例（38.1%）观察到过表达bcl-2的细胞数量略有增加，治疗后凋亡指数降低。结论：经过三个月的内分泌联合治疗后，少数临床局限性前列腺肿瘤显示退行性上皮改变，并伴有肿瘤细胞凋亡的增加；凋亡指数降低的13个肿瘤中，有5个肿瘤细胞过表达bcl-2增加。
AIMS: Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. METHODS: Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bcl-2 overexpression by immunohistochemistry. RESULTS: All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09% and 1.73%, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71% (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of < 7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bcl-2 was observed in five of the 13 tumours (38.1%) with reduced apoptotic indices after therapy. CONCLUSIONS: After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bcl-2 was observed in five of the 13 tumours with reduced apoptotic indices.
登录
查看更多内容
雄激素消融后 PC-82 人类前列腺癌消退过程中的程序性细胞死亡。
影响因子：
11.2
作者：
Kyprianou,N;English,HF;Isaacs,JT
通讯作者：
Isaacs,JT
临床局限性前列腺癌中 p53 突变的频率和特征。
影响因子：
2.1
作者：
Hall,MC;Navone,NM;Troncoso,P;Pollack,A;Zagars,GK;vonEschenbach,AC;Conti,CJ;Chung,LW
通讯作者：
Chung,LW
影响因子：
3.3
作者：
AIHARA, M;TRUONG, LD;THOMPSON, TC
通讯作者：
THOMPSON, TC
检测激素难治性人类前列腺癌中的凋亡抑制癌蛋白 bc1-2。
DOI：
--
发表时间：
1993
期刊：
The American journal of pathology
影响因子：
--
作者：
Colombel,M;Symmans,F;Gil,S;O'Toole,KM;Chopin,D;Benson,M;Olsson,CA;Korsmeyer,S;Buttyan,R
通讯作者：
Buttyan,R
p53 和 MDM-2 基因的改变在临床局限性 B 期前列腺腺癌中并不常见。
DOI：
--
发表时间：
1994
期刊：
The American journal of pathology
影响因子：
--
作者：
Ittmann,M;Wieczorek,R;Heller,P;Dave,A;Provet,J;Krolewski,J
通讯作者：
Krolewski,J